Amgen Inc. Announces Impressive Second Quarter Results

Amgen Inc. has unveiled its financial achievements for the second quarter of fiscal 2025, showcasing a remarkable 9% increase in revenue, reaching $9.2 billion compared to the previous year. The period ending June 30 also saw net income and diluted earnings per share leap by 92%, amounting to $1.4 billion and $2.65, respectively.

First Half Fiscal 2025 Highlights

The first half of the year was equally impressive, with revenue climbing to $17.3 billion from $15.8 billion in the same period in 2024. Net income and diluted EPS experienced a dramatic rise, from $633 million to $3.2 billion and from $1.17 to $5.84, respectively. Amgen remains optimistic, maintaining its full-year revenue forecast between $35 billion and $36 billion.

Leadership's Vision for the Future

"Our commitment to delivering innovative medicines and biosimilars is yielding tangible results, enabling us to reach more patients and tackle serious diseases head-on. Our investments in scientific research are paving the way for healthier lives and ensuring sustainable growth," stated CEO Robert Bradway. Reflecting this positive outlook, Amgen's stock saw a modest increase of 0.28% in after-hours trading.